Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of Comparative Neurology|February 18, 2026
Cortical Type: The Basis for a Modern Neurodevelopmental Synthesis (Ontogeny, Phylogeny, Synaptic Connectivity) of the Human Cerebral CortexJosefa Zaldivar-Diez, Miguel Ángel García-Cabezas
ACS Chemical Neuroscience|February 8, 2017
Classics in Chemical Neuroscience: HaloperidolMarshall W Tyler, Josefa Zaldivar-Diez, Stephen J Haggarty
Movement Disorders : Official Journal of the Movement Disorder Society|February 12, 2026
Quantitative Analysis of Locus Coeruleus Neurons and Thalamic Noradrenergic Axons in a Progressive 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Monkey Model of Parkinson's DiseaseMegan Carrillo, Nagore Hernández-Pinedo, Josefa Zaldivar-Diez, et al.
Neurobiology of Aging|October 2, 2020
Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse modelSara Castro-Sánchez, Josefa Zaldivar-Diez, Enrique Luengo, et al.
Elife|September 18, 2025
Recovery of the full in vivo firing range in post-lesion surviving DA SN neurons associated with Kv4.3-mediated pacemaker plasticityLora Kovacheva, Josef Shin, Josefa Zaldivar-Diez, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|January 25, 2017
Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosaMiguel Marchena, Beatriz Villarejo-Zori, Josefa Zaldivar-Diez, et al.
Journal of Medicinal Chemistry|December 12, 2019
Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic FateJosefa Zaldivar-Diez, Lingling Li, Ana M Garcia, et al.
European Journal of Medicinal Chemistry|July 9, 2017
Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agentsIrene G Salado, Josefa Zaldivar-Diez, Víctor Sebastián-Pérez, et al.
Journal of Medicinal Chemistry|August 7, 2018
Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation InhibitorsAnnachiara Gandini, Manuela Bartolini, Daniele Tedesco, et al.
Pageof 1